Pharvaris

Pharvaris is a Switzerland-based biotechnology startup founded in 2015 with the slogan "Pioneering science for patient choice." The company is dedicated to bringing oral bradykinin-B2-receptor antagonists to patients, focusing on developing alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. With a team of executives possessing extensive expertise in pharmaceutical development and rare disorders, including HAE, Pharvaris is at the forefront of innovation.

Having reunited the core team responsible for the discovery and approval of the HAE treatment icatibant, Pharvaris is leveraging novel small molecules to advance potent, orally available compounds targeting this clinically proven therapeutic target. The company's commitment to pioneering science and patient choice has been reinforced by a recent $300.00M Post-IPO Equity investment on 06 December 2023. Although the specific investors of this recent funding round were not disclosed, it reflects a significant level of confidence in Pharvaris' mission and potential within the biotechnology, health care, life sciences, and pharmaceutical industries.